Literature DB >> 12162776

Inducible cyclooxygenase and interleukin 6 gene expressions in nasal polyp fibroblasts: possible implication in the pathogenesis of nasal polyposis.

Chia-Ming Liu1, Chi-Yuan Hong, Chia-Tung Shun, Tzu-Yu Hsiao, Chih-Chiang Wang, Juo-Song Wang, Michael Hsiao, Sze-Kwan Lin.   

Abstract

BACKGROUND: Inflammation is believed to be related to the pathogenesis of nasal polyp (NP). Inducible cyclooxygenase (COX-2) and interleukin (IL) 6 are important mediators of inflammation. However, no information is available regarding the expression of these mediators in nasal polyp fibroblasts (NPFs). The inductive effects of proinflammatory cytokines (IL-1alpha or tumor necrosis factor alpha) alone or in combination with prostaglandin E(2) on IL-6 and COX-2 messenger RNA (mRNA) synthesis in NPFs were investigated.
DESIGN: The expressions of IL-6 and COX-2 mRNAs in NPFs and in 34 surgical specimens of NP were detected by Northern blot and in situ hybridization.
RESULTS: Significant amounts of constitutive IL-6 and COX-2 mRNAs were produced in NPFs. Cytokines induced IL-6 and COX-2 mRNA synthesis in NPFs. Meloxicam (a specific COX-2 inhibitor) suppressed the induction of cytokines on IL-6 mRNA levels, and these effects could be reversed by exogenous prostaglandin E(2). In situ hybridization revealed that IL-6 and COX-2 mRNAs were detected primarily in fibroblasts, macrophages, and plasma cells. Aggregation of plasma cells as well as collagen deposition in vicinity to IL-6 mRNA-producing fibroblasts was found. Rich vascularity around COX-2 mRNA(+) fibroblasts was also identified.
CONCLUSIONS: The pathogenesis of nasal polyposis involves NPFs through synthesizing IL-6 to modulate the activation of immune responses (plasma cell formation) and synthesis of stroma. Inducible cyclooxygenase also contributes to NP development by promoting vasodilatation and modulating the cytokine-induced IL-6 gene expression in NPFs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12162776     DOI: 10.1001/archotol.128.8.945

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  7 in total

1.  Correlation between cytokine levels in nasal fluid and scored clinical parameters in patients with nasal polyposis.

Authors:  Aleksandar Perić; Danilo Vojvodić; Aneta V Perić; Vesna Radulović; Olivera Miljanović
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2012-01-03

Review 2.  Imaging of rhinosinusitis and its complications: plain film, CT, and MRI.

Authors:  Mahmood F Mafee; Brandon H Tran; Ajay R Chapa
Journal:  Clin Rev Allergy Immunol       Date:  2006-06       Impact factor: 8.667

3.  Interleukin 5, IL6, IL12, IFN-gamma, RANTES and Fractalkine in human nasal polyps, turbinate mucosa and serum.

Authors:  Arild Danielsen; Turid Tynning; Karl A Brokstad; Jan Olofsson; Ake Davidsson
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-02-03       Impact factor: 2.503

4.  PPARgamma pathway activation results in apoptosis and COX-2 inhibition in HepG2 cells.

Authors:  Ming-Yi Li; Hua Deng; Jia-Ming Zhao; Dong Dai; Xiao-Yu Tan
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

Review 5.  Pathophysiology of chronic rhinosinusitis, pharmaceutical therapy options.

Authors:  Claus Bachert; Gabriële Holtappels
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2015-12-22

Review 6.  Cyclooxygenases and the pathogenesis of chronic rhinosinusitis and nasal polyposis.

Authors:  Josep M Guilemany; Jordi Roca-Ferrer; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2008-05       Impact factor: 4.919

7.  Differential expression of tumor necrosis factor α, interleukin 1β, nuclear factor κB in nasal mucosa among chronic rhinosinusitis patients with and without polyps.

Authors:  Danuta Plewka; Alicja Grzanka; Elzbieta Drzewiecka; Andrzej Plewka; Maciej Misiołek; Grażyna Lisowska; Beata Rostkowska-Nadolska; Radoslaw Gawlik
Journal:  Postepy Dermatol Alergol       Date:  2017-05-29       Impact factor: 1.837

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.